IDENTIFICATION OF OXACILLIN RESISTANT STRAINS OF STAPHYLOCOCCUS AUREUS

金黄色葡萄球菌苯唑西林耐药菌株的鉴定

• 批准号: 3853120
• 负责人: C H ZIERDT
• 金额: --
• 依托单位: CLINICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3853120
• 关键词: Staphylococcus aureus; bacterial virus; genetic strain; microorganism culture; nosocomial infections

A multi-center study of oxacillin resistant S. aureus is in place and should be completed within a year. Phage types have been, and will continue to be used to fingerprint strains of the oxacillin resistant species. We have evidence that strains with oxacillin resistance not reversible by clavulanic acid are few in number, and that oxacillin resistant S. aureus is represented in many U. S. hospitals by a single predominant strain. S. aureus in which oxacillin resistance is reduced in the presence of clavulanic acid, the hyperbetalactamase producers, have another, distinct phage pattern. We also are studying loss rates of oxacillin resistance after the strains are cultured from the treated patient. This phase will include initial sensitivity tests done directly from clinical samples, followed by tests done during serial subcultures. This has important bearing on sensitivity testing of these S. aureus strains, since they begin to lose resistance immediately, on initial cultures. Progress: This study is completed. It turned out to be very interesting. It supplied confirmatory as well as new data on the epidemiology of oxacillin resistant S. aureus (ORSA) and hyperbetalactamase producing S. aureus (HBLPSA). ORSA and HBLPSA are distinct strains of epidemic S. aureus. ORSA representing the world-wide phage group III epidemic strain are disappearing from the Clinical Center. Two recent ORSA isolates in the Clinical Center, unrelated to the world-wide strains, were community- derived. HBLPSA is comprised of a single phage Group V strain, in the Clinical Center and in many U. S. Hospitals. This S. aureus strain has an elevated capacity to cause infections. The study to determine loss rates of oxacillin resistance, during in vitro growth, was dropped. Some variables were deemed too difficult to control, and technical help was unavailable.

苯唑西林耐药沙门氏菌的多中心研究。金黄色葡萄球菌已就位， 应在一年内完成。 噬菌体类型已经，并将 继续用于对苯唑西林耐药菌株进行指纹识别 物种 我们有证据表明苯唑西林耐药菌株 可逆的克拉维酸的数量很少，苯唑西林 耐甲氧西林金黄色葡萄金黄色葡萄球菌在许多美国S.一个医院 优势菌株 S.金黄色 其中苯唑西林抗性降低 在存在克拉维酸的情况下，高β内酰胺酶产生者， 另一种不同的噬菌体模式。 我们也在研究 苯唑西林耐药性后，菌株培养从处理 病人 该阶段将包括直接进行的初始敏感性测试 从临床样本中，然后在连续传代培养期间进行检测。 这对敏感性试验具有重要意义。金黄色 菌株，因为它们开始立即失去抗性，在初始 cultures. 进度： 这项研究已经完成。 结果非常有趣。 它 提供了关于苯唑西林流行病学的确证性和新数据 耐甲氧西林金黄色葡萄金黄色葡萄球菌（ORSA）和产高β-内酰胺酶的S.金黄色 （HBLPSA）。 ORSA和HBLPSA是流行性链球菌的不同菌株。金黄色。 代表世界范围内噬菌体III组流行株的ORSA是 从临床中心消失 两个最近的ORSA分离株在 临床中心，与世界各地的菌株无关，是社区- 推导 HBLPSA由单个噬菌体V组菌株组成，在临床上， 中心和许多美国。S.医院的 这个S。金黄色葡萄球菌菌株具有升高的 有能力造成感染。 研究确定的损失率 在体外生长期间，苯唑西林抗性下降。 一些变量 被认为太难控制，技术帮助不可用。